Philadelphia, Pennsylvania May 23-27, 2012
WALTHAM, Mass.--(BUSINESS WIRE)--May 23, 2012-- NeuroMetrix, Inc.
(Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that it will be an exhibitor at the American Association of Clinical Endocrinologists' (AACE) 21st Annual Scientific and Clinical Congress. The AACE Annual Meeting will be held at the Marriott Philadelphia Downtown and The Pennsylvania Convention Center.
NeuroMetrix will feature the NC-stat(R) DPNCheck(TM), a medical device providing a fast, accurate, and quantitative point-of-care test for the detection of systemic neuropathies such as diabetic peripheral neuropathy (DPN). DPN affects over 50% of people with diabetes and can lead to foot ulcers and amputation. Since commercial launch of NC-stat DPNCheck in late 2011, the company has attracted an expanding customer base of physicians, including endocrinologists. NC-stat DPNCheck is also being successfully introduced into managed care and retail health organizations.
The company will also discuss the SENSUS(TM) pain management device which is under development and is designed to help patients manage chronic pain, such as painful diabetic neuropathy. NeuroMetrix recently filed a 510(k) premarket notification with the Food and Drug Administration (FDA) for SENSUS. The device has not been cleared by FDA and is not available for commercial distribution.
"The AACE Annual Meeting is an important event for endocrinologists, including those with a practice focus on diabetes," said Shai N.
Gozani, M.D., Ph.D., President and Chief Executive Officer, NeuroMetrix. "This meeting provides us the opportunity to discuss with the endocrinology community our approaches to DPN, which is one of the leading complications of diabetes." About NeuroMetrix NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices, associated consumables, and support software for the treatment and management of diabetes and its complications. The company is focused on nerve related complications of diabetes, called diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company's products are used by physicians and other clinicians, in retail health settings such as pharmacies, and by managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat(R) DPNCheck(TM) device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company is in late stage development of SENSUS(TM), a pain management device that will be used to treat painful diabetic neuropathy, a form of chronic intractable pain. Currently, painful diabetic neuropathy is treated pharmacologically, which is a $2 billion annual market. The company has additional therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.
CONTACT: NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761 Chief Financial Officer firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS PENNSYLVANIA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL DIABETES SOURCE: NeuroMetrix Copyright Business Wire 2012 PUB: 05/23/2012 01:20 PM/DISC: 05/23/2012 01:20 PM http://www.businesswire.com/news/home/20120523006334/